November 2015- Volume 11, Issue 11

In this Issue

Diagnostics

Prenatal testing: quo vadis?

Prenatal testing: quo vadis?

Hastings Center awarded NIH grant for major project on goals and practices of next-generation prenatal testing

Fragile blood vessels

Fragile blood vessels

UCLA MRI technology may help in diagnosing cardiovascular diseases and dementia through vascular compliance

A new tool to predict outcomes of kidney cancer treatment

A new tool to predict outcomes of kidney cancer treatment

Research indicates that expression levels of a key protein involved in tumor cell survival could predict response to first-line therapies targeting VEGF

It’s all about image

It’s all about image

Progenics hopes to acquire EXINI and combine EXINI’s imaging analysis with its own prostate cancer imaging products

Business & Government Policy

Patent Docs: Federal Circuit changes the rules for biosimilar litigation

Patent Docs: Federal Circuit changes the rules for biosimilar litigation

Court of Appeals for the Federal Circuit renders fractured decision construing the terms of Biologics Price Control and Innovation Act for the first time

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Discovery

A ‘shock’ to the system

A ‘shock’ to the system

Small heat shock protein could be a model for new forms of Alzheimer’s therapy

Sifting through the genome

Sifting through the genome

Six NIH grants worth $13 million support research into finding the genomic variants that make a difference

The mediation of mTORC1

The mediation of mTORC1

New findings open opportunities for creating new medicines for metabolic, musculoskeletal, autoimmune and other age-related diseases

In-licensing inhibitors

In-licensing inhibitors

Horizon, Servier ink an in-licensing and option agreement for novel kinase inhibitors

Commentary

Out of order: You treat what you are

Out of order: You treat what you are

Despite so many achievements in pharma and biotech, the developing world continues to be ravaged by microbial infection, and that's something we ought to pay more attention to

Guest commentary: Immunotherapy research takes a lead showcasing innovative cancer models and translational platforms

Guest commentary: Immunotherapy research takes a lead showcasing innovative cancer models and translational platforms

As the design of anticancer agents has evolved, the processes, methods and equipment used to aid the fight against cancer have too, leading to the resurgence of immunotherapy as a powerful way of fighting cancer

Research & Development

Making models of cells

Making models of cells

TSRI and UC San Diego launch new consortium to create ‘Virtual Cell’

Golden touch with zinc fingers

Golden touch with zinc fingers

MIT researchers use zinc fingers to detect DNA sequence and then pull trigger on cancer cells

Stem cells lead to improved neurotoxicity tests

Stem cells lead to improved neurotoxicity tests

UW-Madison aims to improve accuracy and reduce cost compared to animal studies of toxicity

Lilly and Innovent kick oncology R&D pact to next level

Lilly and Innovent kick oncology R&D pact to next level

New deal between Eli Lilly and Innovent around bispecific antibodies could be worth $1 billion

Preclinical

Eye on the prize

Eye on the prize

Peer-reviewed publication of preclinical efficacy results for TxCell’s Col-Treg points to therapeutic potential in autoimmune uveitis

Money for something in RSV

Money for something in RSV

RSV vaccine findings net Novavax an $89-million Gates Foundation grant

Preclinical promise for FS102

Preclinical promise for FS102

F-star partners with BMS on potential treatment of HER2-positive cancers

Clinical Trials

Times are a-changin’ for rare diseases

Times are a-changin’ for rare diseases

Medgenics acquires NFC-1, a ‘game-changer’ for rare neurogenetic disorder

Knocking out kallikrein

Knocking out kallikrein

BioCryst Phase 1 study of BCX7353 achieves objectives for potential hereditary angioedema drug

Focusing on rare and ultra-rare diseases

Focusing on rare and ultra-rare diseases

Ultragenyx reports positive results from Phase 2 study of UX007 in long-chain fatty acid oxidation disorder patients

Positive progress for CIC in Phase 3

Positive progress for CIC in Phase 3

Ironwood’s linaclotide reaches primary endpoint in chronic idiopathic constipation trial

Contract Services

Recording, analyzing and reporting

Recording, analyzing and reporting

BioClinica acquires Synowledge to add to drug safety and regulatory business process capabilities

Type 1 diabetes targeted

Type 1 diabetes targeted

Caladrius Biosciences and Sanford Research establish strategic collaboration to drive major advance in treatment of type 1 diabetes

Dealing in New Delhi

Dealing in New Delhi

Contract manufacturing in India up 20 percent with expected CAGR of 17 to 18 percent

Special Reports

Editor's Focus

Getting the cure where it needs to go

Getting the cure where it needs to go

A roundup of some recent news of delivery options for therapeutics, since it's a subject that's often hard to find a home for in our usual news sections

Feature

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022